Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGMNUE)

Drug Name
AM0010 Drug Info
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 3 [1]
Pancreatic ductal carcinoma 2C10.0 Phase 3 [2]
Non-small-cell lung cancer 2C25.Y Phase 1 [3]
Renal cell carcinoma 2C90 Phase 1 [3]
Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
Cross-matching ID
TTD Drug ID
DMGMNUE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Modulator [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-10 (IL10) DTT IL10 5.87 4.853 5.092 5.629
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Pancreatic cancer
ICD Disease Classification 2C10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-10 (IL10) DTT IL10 1.07E-02 0.08 0.56
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02009449) A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of ARMO BioSciences.